CD274 and metabolic syndrome: These results suggest that, in addition to PD-L1 and prior use of broad-spectrum antimicrobials, MetS is an independent prognostic factor in patients with advanced lung cancer treated with immune checkpoint inhibitors +/- chemotherapy.